Get started
SANOFISS

SANOFI

109.06EURD
+0.26+0.23%
At close at Mar 7, 15:40 GMT
EUR
No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Forecast Seasonals Bonds

SANP trade ideas

Sanofi (SNY): A Strong Investment CaseCompany Overview: Sanofi NASDAQ:SNY is a major pharmaceutical company based in Paris, with a market capitalization of $134 billion. Investment Highlights: Dividend Yield: 3.8%, more than double the S&P 500 average. Drug Portfolio: Diverse and includes successful drug developments. Pipeline: Promising future drug pipeline with potential for growth. Berkshire Hathaway Investment: Long-standing investment from Berkshire Hathaway underscores the company’s attractiveness and stability. Outlook: We are bullish on SNY due to its growth potential and solid dividend payout. The combination of a strong drug portfolio, promising pipeline, and robust dividend makes Sanofi a compelling investment choice. #Sanofi #SNY #Pharmaceuticals #Investment #DividendYield #MarketCap #GrowthPotential #BerkshireHathaway #StockAnalysis #Bullish
NASDAQ:SNYLong
by Richtv_official
Is Sanofi Undervalue by 22% ?I wanted to share an analysis I've conducted on Sanofi over the past five years using both comparable methods and a 2-Stage DCF approach. According to my findings, the market value appears to be at least 22% undervalued in comparison with its fair value. Moreover, considering the post-COVID effects on pharmaceutical companies, I believe Sanofi presents a compelling opportunity to purchase its stock with potentially lower risk. I would be glad to share my detailed analysis for any one interested in more in debt explorations Disclaimer: This information is based on my personal analysis and is not to be considered financial advice. I am expressing my own views and opinions on the current market conditions and Sanofi's stock. Always conduct your own research and consider seeking advice from a qualified financial professional before making any investment decisions.
ELong
by arya1992
Sanofi S.A. (SAN.pa) bearish scenario:The technical figure Channel Up can be found in the daily chart in the French company Sanofi S.A. (SAN.pa). Sanofi S.A. is a French multinational pharmaceutical and healthcare company. Sanofi engages in the research and development, manufacturing and marketing of pharmacological products, principally in the prescription market, but the firm also develops over-the-counter medications. The corporation covers seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines (it is the world's largest producer of the last through its subsidiary Sanofi Pasteur). The Channel Up broke through the support line on 24/01/2023. If the price holds below this level, you can have a possible bearish price movement with a forecast for the next 26 days towards 86.54 EUR. According to experts, your stop-loss order should be placed at 92.90 EUR if you decide to enter this position. French drugmaker Sanofi SA plans to launch a drug for rare bleeding disorder hemophilia A this year, Chief Executive Officer Paul Hudson told CNBC in an interview last week. The U.S. Food and Drug Administration last year accepted the marketing application for the therapy, which is being developed in collaboration with Swedish drugmaker Sobi, and is expected to decide on an approval status by Feb. 28. Hemophilia A is an inherited bleeding disorder in which the blood does not clot normally. About 400 babies are born with this condition every year, although the exact number of people affected is not known, according to government data. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
EShort
by legacyFXofficial
Key levels for SANOFIThe algorithm is showing a very profitable pattern in SANOFI. First, if the price breaks up we have a clear rally until the top of the channel with a tight stop loss slightly below the break point. On the other hand, if the market is moving down, we should see a break to the downside of the channel, then an easy break of the support and the blue line would be the last support before we see a major correction to 83$, where 3 different patterns are pointing out as a clear support area where demand will come back. Good luck!
E
by TopChartPatterns
Sanofi found support at previous resistance.Sanofi - 30d expiry - We look to Buy a break of 88.01 (stop at 84.48) Previous resistance level of 88 broken. Our short term bias remains positive. Previous resistance, now becomes support at 88. 50 1day EMA is at 86.97. Support is located at 88 and should stem dips to this area. Daily signals are mildly bullish. Our profit targets will be 96.72 and 97.72 Resistance: 91.00 / 92.90 / 95.00 Support: 90.00 / 88.00 / 86.20 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis , like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis , as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
ELong
by Saxo
Buying Sanofi break of resistance.Sanofi - 30d expiry - We look to Buy a break of 88.41 (stop at 84.78) Previous resistance level of 83 broken. Short term bias has turned positive. 88.34 has been pivotal. A break of the recent high at 88.34 should result in a further move higher. Prices have reacted from 81.93. Overnight losses have been limited. Our outlook is bullish. Our profit targets will be 97.48 and 99.48 Resistance: 88.40 / 91.00 / 95.00 Support: 86.00 / 84.00 / 82.00 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis , like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis , as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
ELong
by Saxo
Buying Sanofi correction higher.Sanofi - Intraday - We look to Buy a break of 83.71 (stop at 79.98) We are trading at oversold extremes. Bullish divergence can be seen on the daily (the chart makes a lower low while the oscillator makes a higher low), often a signal of exhausted bearish momentum, or at least a correction higher. 83.58 has been pivotal. A break of 83.60 is needed to confirm follow through bullish momentum. Although the bears are in control, the stalling negative momentum indicates a turnaround is possible. Posted a Double Bottom formation. Further upside is expected, however, due to the strong resistance above we prefer to buy a break of 83.70, which will confirm the bullish sentiment. Our profit targets will be 92.69 and 95.69 Resistance: 83.00 / 87.50 / 90.00 Support: 80.00 / 77.00 / 75.00 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis , like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis , as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
ELong
by Saxo
Sanofi - Pharming for profits?Sanofi Short Term We look to Buy at 95.00 (stop at 91.90) The medium term bias remains bullish. Levels close to the 50% pullback level of 93.25 found buyers. Previous support located at 93.08. Further upside is expected and we look to set longs in early trade. Our profit targets will be 104.35 and 110.00 Resistance: 95.16 / 98.22 / 104.35 Support: 93.25 / 93.08 / 92.78 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
ELong
by Saxo
SNY Fib Levels On The Radar & WhySNY and TBIO buttoned up the news this morning sending a bunch of other biotech stocks running higher. Now that this is out of the way, levels could be important for longs looking for "what's next" and the 236 Fib level seems to be that area to watch. It was an area that the volatile SNY stock settled above for weeks and now is an area it hasn't been able to break above for the last several weeks. Heading into the month after this acquisition, it's gonna be interesting to see if mRNA stocks start to catch a bit more. " A mega buyout from Sanofi (NASDAQ: SNY) has investors looking at biotech stocks today. If you remember our article, “Top Biotech Penny Stocks On Robinhood To Watch This Week,” we discussed Sanofi and its strengthening relationship with a former penny stock, Translate Bio Inc. (NASDAQ: TBIO)...Sanofi had previously pledged to invest 400 million euros annually in a vaccines R&D facility to advance mRNA vaccines with Translate to benefit. Tuesday, Sanofi formally announced a $3.2 billion buyout of its vaccine collaboration partner. This was at $38 a share in cash, roughly 30% higher than the close on August 2nd. " Quote Source & Read More: Hot Biotech Stocks To Watch After Sanofi’s Acquisition Of Translate Bio
N
by PennyStocks101